Alterations in the serum proteome profile during the development of ovarian cancer

Abstract

Abstract. Ovarian cancer causes more deaths than any other malignant tumor of the female reproductive system. This is because the condition usually goes undetected until the late stages. The purpose of the present study is to identify alterations in the serum proteome profile during the development of ovarian cancer and to provide an experimental basis for discovering new and valuable serum biomarkers for the early detection of ovarian carcinoma. Surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF-MS) was used to profile changes in the serum proteome of Fischer 344 rats with ovarian cancer during the progress of tumor development. Sera were collected from the rats on day A (1 week before injection of tumor cells), day B (4 weeks after injection), and day C (6 weeks after injection). Each sample was subjected to SELDI-TOF-MS testing. Peak detection and alignment and selection of peaks with the highest discriminatory power were performed using ProteinChip biomarker software. Decision tree analyses were performed using biomarker pattern software. Finally, 3 peaks were found to be the most valuable ones (3759, 4659 and 9318 Da). The expression frequency of m/z 3759-Da peaks was downregulated and another two frequencies (4659 and 9318 Da) were upregulated, and the levels of expression of these three proteins showed the same tendency as the expression frequency during the development of ovarian cancer. The total accuracy rate of diagnosis at 4 and 6 weeks post-injection was 94.7 and 97.3%, respectively. Profiling the serum proteome changes during the process of the cancer development using SELDI-TOF-MS may provide useful information regarding carcinogenesis and facilitate discovery of novel serum biomarkers for early detection.

Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer

“…Hence, our hope is that additional studies will be performed adhering to the study design principles described herein to discover novel serum protein signatures to improve not only the early detection of ovarian cancer, but also the guidance on ovarian cancer therapy. Biomarker research is now focusing on the discovery of different biomarkers either in serum or plasma expressed in different stages and different subtypes of the disease [ 17 , 196 , 197 , 198 ].…”

Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer

“…Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis that induces the formation of novel blood vessels, and growth and metastasis of cancers. Several researches have revealed that VEGF plays an important role in promoting endothelial cell proliferation and migration, and induces a direct effect on cancer proliferation and invasiveness (Awazu et al 2013;Hu et al 2013;Sun et al 2014). It has been reported that TBC domain containing proteins also participate in cancer proliferation and angiogenesis via VEGF (Kim et al 2003;Ji et al 2004).…”

MicroRNA-126 affects ovarian cancer cell differentiation and invasion by modulating expression of vascular endothelial growth factor

“…The growth and spread of tumors depends on the formation of an adequate vascular support and amoeboid mode of tumor cell invasion (9). Furthermore, several studies have indicated that VEGF serves a role in promoting endothelial cell proliferation and migration, and induces a direct effect on cell proliferation and invasiveness (3,10,11). Previous studies have indicated that suppressing the expression or activity VEGF in ovarian cancer cells may represent a potential anticancer therapy (12)(13)(14).…”